Solid Biosciences Inc. Revenue from Related Parties
Solid Biosciences Inc. (SLDB) reported Revenue from Related Parties of $8.09 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromRelatedParties · last filed 2023-05-11
- Solid Biosciences Inc. revenue from related parties for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Solid Biosciences Inc. revenue from related parties for the quarter ending 2022-06-30 was $6.17M, a 71.65% increase year-over-year.
- Solid Biosciences Inc. revenue from related parties for the quarter ending 2022-03-31 was $1.93M, a 42.28% decline year-over-year.
- Solid Biosciences Inc. revenue from related parties for the quarter ending 2021-09-30 was $3.54M.
| Period end | Revenue from Related Parties 3 month | Revenue from Related Parties 6 month | Revenue from Related Parties 9 month |
|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $6.17M derived: sum of 2 quarters · filed 2022-11-10 | $8.09M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $6.17M 10-Q · filed 2022-08-11 | $8.09M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $1.93M 10-Q · filed 2023-05-11 | ||
| 2021-09-30 | $3.54M 10-Q · filed 2022-11-10 | $7.13M derived: sum of 2 quarters · filed 2022-11-10 | $10.47M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $3.59M 10-Q · filed 2022-08-11 | $6.93M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $3.33M 10-Q · filed 2022-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |